



This list of clinical research protocols relating to neuro-oncology is compiled for your convenience.

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at http://www.cancer.gov/clinical_trials.

A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.

SELECTED CLINICAL RESEARCH PROTOCOLS RELATING TO NEURO-ONCOLOGY

Phase III

SWOG-S0001 Phase III Randomized Study of Radiotherapy and Carmustine With or Without O6-Benzylguanine in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Chairperson: Alexander Spence. Telephone: 206-543-0252. Lead organization: Southwest Oncology Group. Age range: 18 and over.

Phase II

DUMC-2421-02-2R1, DUMC-2421-01-2, NCI-1253 Phase II Study of ZD 1839 in Patients With Glioblastoma Multiforme in First Relapse

Chairperson: Henry Friedman. Telephone: 919-684-3377. Lead organization: Duke Comprehensive Cancer Center. Age range: 18 and over.

NABTC-9901 Phase II Study of Tipifarnib in Patients With Recurrent or Progressive Malignant Glioma

Chairperson: Timothy Cloughesy. Telephone: 310-825-5321. Lead organization: North American Brain Tumor Consortium. Age range: 18 and over.

DFCI-01278, CELGENE-2001-P-001757/3, NCI-G02-2117 Phase II Study of Thalidomide, Celecoxib, Etoposide, and Cyclophosphamide in Patients With Relapsed or Refractory Malignant Glioma

Chairperson: Patrick Y. Wen. Telephone: 617-632-2166. Lead organization: Dana-Farber Cancer Institute. Age range: 18 and over.

RTOG-BR-0013, RTOG-DEV-1072 Phase II Study of Radiothera-

py Followed By Sustained Release Intratumoral Bleomycin in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Chairperson: Roy A. Patchell. Telephone: 859-323-5672. Lead organization: Radiation Therapy Oncology Group. Age range: adult.

NABTC-0105 Phase II Study of Poly ICLC and Radiotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme

Chairperson: Larry Junck. Telephone: 734-936-9055 or 1-800-865-1125. Lead organization: North American Brain Tumor Consortium. Age range: 18 and over.

NCI-03-C-0018 Phase II Study of LY317615 in Patients With Recurrent High-Grade Gliomas

Chairperson: Howard A. Fine. Telephone: 301-402-6298. Lead organization: Center for Cancer Research. Age range: 18 and over.

SWOG-S9811 Phase II Study of Hydroxyurea in Patients With Unresectable Benign Meningioma

Chairperson: Lode Swinnen. Telephone: 708-327-3142. Lead organization: Southwest Oncology Group. Age range: 18 and over.

EORTC-16011, EORTC-26013 Phase II Study of Imatinib Mesylate in Patients With Gliomas

Chairperson: Eric Raymond. Telephone: +33-1-42-11-4289. Lead organization: EORTC New Drug Development Group. Age range: 18 and over.

NCCTG-N997B Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme

Chairperson: Evanthia Galanis. Telephone: 507-284-2511. Lead organization: North Central Cancer Treatment Group. Age range: 18 and over.

WSU-C-1403-BT, NCI-G99-1567 Phase II Study of Autologous Cancer Antigen Specific Immunotherapy in Patients With Malignant Glioma

Chairperson: Andrew Sloan. Telephone: 313-966-7388 or 800-527-6266. Lead organization: Barbara Ann Karmanos Cancer Institute. Age range: 18 and over.

DFCI-00302, CELGENE-2000-P-002521/1, NCI-G02-2118 Phase II Study of Adjuvant Temozolomide, Thalidomide, and Celecoxib After Radiotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme

Chairperson: Patrick Y. Wen. Telephone: 617-632-2166. Lead organization: Dana-Farber Cancer Institute. Age range: 18 and over.

RTOG-BR-0023, RTOG-DEV-1040 Phase II Study of Accelerated Radiotherapy With Conformal Stereotactic Radiotherapy Boost Followed by Carmustine in Patients With Supratentorial Glioblastoma Multiforme

Chairperson: Rupert Schmidt-Ullrich. Telephone: 804-828-7232. Lead organization: Radiation Therapy Oncology Group. Age range: not specified.

NABTT 2109 Phase II Study of Methotrexate and Thiotepa Chemotherapy for Patients With Newly Diagnosed Primary CNS Lymphoma
Chairperson: Tracy Batchelor. Telephone: 617-724-8770. Lead

organization: Massachusetts General Hospital. Age range: 18 and older.

MCC 13103 Phase II Study to Evaluate the Effect of Dalteparin and Radiation Therapy on Survival Compared to the RTOG RPA Database and on Thromboembolic Events in Patients With Newly Diagnosed Glioblastoma Multiforme

Chairperson: Susan Snodgrass. Telephone: 813-979-3871. Lead organization: Moffitt Cancer Center. Age range: 18 or older.

MCC 13024 Phase II Trial of Surgical Resection, Gliadel Wafer, and Irradiation Followed by Penicillamine/Low Copper Diet for Newly Diagnosed Glioblastoma Multiforme

Chairperson: Susan Snodgrass. Telephone: 813-979-3871. Lead organization: Moffitt Cancer Center. Age range: 18 or older.

MCC 11904 Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma

Chairperson: Surasak Phuphanich. Telephone: 813-972-8439. Lead organization: Moffitt Cancer Center. Age range: 18 or older.

Phase I/II

JHOC-NABTT-9902, NABTT-9902 Phase I/II Study of Oxaliplatin Followed by Radiotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme

Chairperson: Tracy Batchelor. Telephone: 617-724-8770 or 1-877-726-5130. Lead organization: Sidney Kimmel Comprehensive Cancer

Center at Johns Hopkins. Age range: 18 and over.

JHOC-NABTT-9809, NABTT-9809 Phase I/II Study of Oral COL-3 in Patients With Progressive or Recurrent High Grade Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, or Glioblastoma Multiforme

Chairperson: Pamela New. Telephone: 210-617-5161. Lead organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Age range: 18 and over.

JHOC-NABTT-2005 Phase I/II Study of Irofulven in Patients With Progressive or Recurrent High-Grade Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, or Glioblastoma Multiforme

Chairperson: Steven Rosenfeld. Telephone: 205-934-1432. Lead organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Age range: 18 and over.

NABTC-9907, UCLA-0006095 Phase I/II Study of Irinotecan and Temozolomide in Patients With Recurrent Malignant Glioma

Chairperson: Wai-Kwan Alfred Yung. Telephone: 713-794-1285 or 1-800-392-1611. Lead organization: North American Brain Tumor Consortium. Age range: 18 and over.

NABTC-9908, NCI-01-C-0243, UCLA-0101024 Phase I/II Study of Imatinib Mesylate in Patients With Recurrent Malignant Glioma or Meningioma

Chairperson: Patrick Y. Wen. Telephone: 617-632-2166. Lead organization: North American Brain Tumor Consortium. Age range: 18 and over.

NABTC-0103 Phase I/II Study of Erlotinib in Patients With Recurrent Malignant Glioma

Chairperson: Jeffrey Raizer. Telephone: 212-639-7330. Lead organization: North American Brain Tumor Consortium. Age range: 18 and over.

JHOC-NABTT-2111, NABTT-2111 Phase I/II Study of BMS-247550 in Patients With Recurrent High-Grade Glioma

Chairperson: David M. Peereboom. Telephone: 216-445-6068; 800-862-7798. Lead organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Age range: 18 and over.

NABTT 9911 Phase I/II Trial of EMD 121974 for Treatment of Patients With Recurrent Malignant Gliomas

Chairperson: Louis B. Nabors. Telephone: 205-934-1436. Lead organization: University of Alabama at Birmingham. Age range: 18 or older.

NABTT 9903 Phase I/II Study of Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

Chairperson: Jon Weingart. Telephone: 410-614-3052. Lead organization: Johns Hopkins University. Age range: 18 or older.

Phase I

MSKCC-99114, NCI-G00-1765 Phase I Study of Temozolomide and Carmustine After Radiotherapy in Patients With Malignant Glioma

Chairperson: Jeffrey Raizer. Telephone: 212-639-7330. Lead

organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

NABTT-101-9601, NCI-T96-0052H Phase I Study of Polifeprosan 20 With Carmustine Implant (GLIADEL) in Patients With Recurrent Malignant Glioma

Chairperson: Alessandro Olivi. Telephone: 410-955-0703. Lead organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Age range: 18 and over.

BIOGEN-C-1502, NCI-V02-1696, UARIZ-HSC-01197 Phase I Study of Intratumor BG00001 (Adenoviral Vector Encoding Human Interferon beta) in Patients With Recurrent or Progressive Glioblastoma Multiforme

Chairperson: Steven Rosenfeld. Telephone: 205-934-0930 or 1-800-822-0933. Lead organization: BIOGEN Inc. Age range: 18 and over.

MSKCC-01141, NCI-G02-2066, NEOPHARM-IL13PEI-002-R01 Phase I Study of Continuous Intracerebral Infusion of Interleukin-13 PE38QQR Immunotoxin Before and After Second Resection in Patients With Recurrent Resectable Supratentorial Malignant Glioma

Chairperson: Jeffrey Raizer. Telephone: 212-639-7330. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

JHOC-NABTT-2008, NABTT-2008 Phase I Study of Atrasentan in Patients With Progressive or Recurrent Malignant Glioma

Chairperson: Surasak Phuphanich. Telephone: 813-972-8439. Lead

organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Age range: 18 and over.

JHOC-NABTT-2115, NABTT-2115 Phase I Study of Arsenic Trioxide in Combination With Radiotherapy in Patients With Newly Diagnosed Malignant Glioma

Chairperson: Samuel Ryu. Telephone: 313-916-1021. Lead organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Age range: 18 and over.

NABTT 2116 Phase I Trial to Evaluate Repetitive Intravenous Doses of Gadolinium-Texaphyrin as a Radiosensitizer in Patients With Glioblastoma Multiforme

Chairperson: James L. Pearlman. Telephone: 813-972-8424. Lead organization: Moffitt Cancer Center. Age range: 18 or older.

NABTT 2006 Phase I Evaluation of the Safety of Karenitecin in the Treatment of Recurrent Malignant Gliomas

Chairperson: Stuart Grossman. Telephone: 410-955-8837. Lead organization: Johns Hopkins University. Age range: 18 or older.